CDKN1A and breast cancer: The level of polyubiquitinated proteins and p21, p27, p53, and Bax proteins in wedelolactone-treated MDA-MB-231, MDA-MB-468, and T47D breast cancer cells were analyzed by immunoblotting to further confirm the inhibitory effect of wedelolactone on proteasome.